Biomarkers Consortium – CSC Scientific Symposium

Aligning diverse stakeholders within cancer research to accelerate progress

The Problem
Cancer research is a large and diverse field, making it difficult to coordinate efforts across its many subfields, which are focused on different research goals, cancer types and patient populations.
The Solution
The FNIH Cancer Steering Committee Scientific Symposium provides an annual forum for academics, nonprofit/industry partners and regulators to convene, fostering coordination and communication across the cancer research field.


The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Cancer Steering Committee (BC-CSC) annually convenes more than 200 experts from academia, pharmaceutical companies, biotechnology companies, not-for-profit organizations, the National Cancer Institute (NCI), the U.S. Food and Drug Administration (FDA) and other federal agencies to focus on biomarker discovery and development across the cancer landscape. The Symposium offers a unique opportunity to prioritize and strategize future directions in biomarker discovery and development. Attendees have an opportunity to explore cutting-edge science, hear feature presentations from experts, brainstorm critical areas of biomarker research need and pitch collaborations designed to inform the field of exciting new advances. 

Topic areas covered include a focus on early diagnosis, difficult to detect tumor types, regulatory hurdles and advancements, analytical validation and clinical utility of liquid biopsy, project opportunities around immune oncology biomarkers, cross-disease analysis of biomarker initiatives in microbiome and Minimal Residual Disease in blood-based cancers and technological progress in AI and imaging. The Symposium highlights the importance of public-private partnership with updates from ongoing pre-competitive BC-CSC projects, as well as provides dedicated networking opportunities to explore potential new collaborations.


Public-Sector Partners 

  • National Cancer Institute
  • Society for Immunotherapy of Cancer (SITC)*
  • U.S. Food and Drug Administration (FDA)

Private Sector Partners

  • Adaptive Biotechnologies*
  • Amgen, Inc.*
  • AstraZeneca Pharmaceuticals, LP*
  • Bayer HealthCare Pharmaceuticals Inc.*
  • Bristol-Myers Squibb Company*
  • Celegene*
  • Genentech, a member of the Roche Group*
  • Genmab*
  • Janssen Oncology*
  • Pfizer, Inc.*
  • Sanofi*
  • Takeda Oncology*

*Provides financial or in-kind support for this program.


  • Discuss cutting edge science, including projects supported by the FNIH BC.
  • Inform the field of the latest developments in critical areas of biomarker science.
  • Guide CSC decision making and project planning.

For more information on how to partner with us, please contact


FNIH Contacts

  • Dana E. Connors, Senior Scientific Program Manager, Cancer Research Partnerships;
  • Stacey J. Adam, Ph.D., Associate Vice President, Research Partnerships;

Results & Accomplishments

Stimulating Interdisciplinary Communication and Collaboration

  • Each year, the Symposium showcases diverse projects across the ecosystem of precision medicine and biomarker development, including those focused on minimal residual disease (MRD), liquid biopsy, novel imaging, cell-free RNA and DNA research and immune oncology. Cross-disease analysis of noncancer biomarker initiatives also helps to spur interdisciplinary collaborations across medicine.

For more information on how to partner with us, please contact